Medicamen Biotech Limited (MEDICAMEQ.NS)
INR 492.8
(-0.58%)
INR 492.8
(-0.58%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.79 Billion INR | 27.29% |
| 2022 | 1.4 Billion INR | 22.02% |
| 2021 | 1.15 Billion INR | 2.42% |
| 2020 | 1.12 Billion INR | -10.19% |
| 2019 | 1.25 Billion INR | 2.36% |
| 2018 | 1.22 Billion INR | 9.95% |
| 2017 | 1.11 Billion INR | 35.23% |
| 2016 | 824.55 Million INR | 22.56% |
| 2015 | 672.75 Million INR | -13.52% |
| 2014 | 777.93 Million INR | 6.21% |
| 2013 | 732.48 Million INR | 14.45% |
| 2012 | 639.97 Million INR | -36.34% |
| 2011 | 1 Billion INR | -18.25% |
| 2010 | 1.22 Billion INR | 21.02% |
| 2009 | 1.01 Billion INR | 17.69% |
| 2008 | 863.35 Million INR | 12.22% |
| 2007 | 769.32 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 430.48 Million INR | -9.03% |
| 2023 Q4 | 473.19 Million INR | 1.76% |
| 2023 FY | 1.79 Billion INR | 27.29% |
| 2023 Q1 | 419.43 Million INR | 8.48% |
| 2023 Q2 | 435.41 Million INR | 3.81% |
| 2023 Q3 | 465.02 Million INR | 6.8% |
| 2022 Q1 | 330.88 Million INR | 45.42% |
| 2022 Q2 | 335.32 Million INR | 1.34% |
| 2022 Q4 | 386.65 Million INR | 8.67% |
| 2022 FY | 1.4 Billion INR | 22.02% |
| 2022 Q3 | 355.81 Million INR | 6.11% |
| 2021 Q4 | 227.53 Million INR | -30.29% |
| 2021 FY | 1.15 Billion INR | 2.42% |
| 2021 Q2 | 325.2 Million INR | 18.13% |
| 2021 Q1 | 275.3 Million INR | 29.62% |
| 2021 Q3 | 326.4 Million INR | 0.37% |
| 2020 Q4 | 212.38 Million INR | -35.49% |
| 2020 Q1 | 277.83 Million INR | 18.1% |
| 2020 Q3 | 329.22 Million INR | 6.99% |
| 2020 Q2 | 307.71 Million INR | 10.76% |
| 2020 FY | 1.12 Billion INR | -10.19% |
| 2019 Q3 | 353.34 Million INR | -0.51% |
| 2019 Q4 | 235.24 Million INR | -33.42% |
| 2019 FY | 1.25 Billion INR | 2.36% |
| 2019 Q1 | 311.29 Million INR | -6.44% |
| 2019 Q2 | 355.15 Million INR | 14.09% |
| 2018 Q4 | 332.7 Million INR | 38.15% |
| 2018 FY | 1.22 Billion INR | 9.95% |
| 2018 Q3 | 240.83 Million INR | -25.87% |
| 2018 Q2 | 324.88 Million INR | -0.84% |
| 2018 Q1 | 327.63 Million INR | 11.82% |
| 2017 Q2 | 279.06 Million INR | 7.3% |
| 2017 Q1 | 260.06 Million INR | 16.71% |
| 2017 Q3 | 282.92 Million INR | 1.38% |
| 2017 Q4 | 293 Million INR | 3.56% |
| 2017 FY | 1.11 Billion INR | 35.23% |
| 2016 Q2 | 229 Million INR | 32.77% |
| 2016 FY | 824.55 Million INR | 22.56% |
| 2016 Q4 | 222.83 Million INR | 11.28% |
| 2016 Q3 | 200.24 Million INR | -12.56% |
| 2016 Q1 | 172.48 Million INR | -4.09% |
| 2015 Q3 | 141.2 Million INR | -21.3% |
| 2015 FY | 672.75 Million INR | -13.52% |
| 2015 Q1 | 172.3 Million INR | -7.22% |
| 2015 Q2 | 179.42 Million INR | 4.13% |
| 2015 Q4 | 179.83 Million INR | 27.36% |
| 2014 Q4 | 185.7 Million INR | 44.03% |
| 2014 Q1 | 190.22 Million INR | -15.05% |
| 2014 Q2 | 273.07 Million INR | 43.55% |
| 2014 Q3 | 128.93 Million INR | -52.78% |
| 2014 FY | 777.93 Million INR | 6.21% |
| 2013 Q4 | 223.91 Million INR | 86.32% |
| 2013 Q3 | 120.18 Million INR | -41.01% |
| 2013 Q1 | 184.64 Million INR | -0.4% |
| 2013 Q2 | 203.74 Million INR | 10.34% |
| 2013 FY | 732.48 Million INR | 14.45% |
| 2012 Q3 | 121.12 Million INR | -45.69% |
| 2012 Q2 | 223.03 Million INR | 101.96% |
| 2012 Q1 | 110.43 Million INR | -64.69% |
| 2012 FY | 639.97 Million INR | -36.34% |
| 2012 Q4 | 185.38 Million INR | 53.05% |
| 2011 Q2 | 488.58 Million INR | 0.0% |
| 2011 Q4 | 312.77 Million INR | 53.39% |
| 2011 FY | 1 Billion INR | -18.25% |
| 2011 Q3 | 203.9 Million INR | -58.27% |
| 2010 FY | 1.22 Billion INR | 21.02% |
| 2009 FY | 1.01 Billion INR | 17.69% |
| 2008 Q4 | 193.07 Million INR | 0.0% |
| 2008 FY | 863.35 Million INR | 12.22% |
| 2007 Q4 | 262.62 Million INR | 0.0% |
| 2007 FY | 769.32 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 97.066% |
| Hester Biosciences Limited | 3.04 Billion INR | 41.123% |
| Aarti Drugs Limited | 25.28 Billion INR | 92.909% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 90.124% |
| Albert David Limited | 3.62 Billion INR | 50.531% |
| Alembic Limited | 1.57 Billion INR | -13.856% |
| Alkem Laboratories Limited | 126.67 Billion INR | 98.585% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -17.604% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 62.125% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -347.87% |
| Brooks Laboratories Limited | 794.86 Million INR | -125.582% |
| Eris Lifesciences Limited | 20.09 Billion INR | 91.075% |
| FDC Limited | 19.42 Billion INR | 90.771% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 92.147% |
| Gufic Biosciences Limited | 8.06 Billion INR | 77.772% |
| Hikal Limited | 17.84 Billion INR | 89.953% |
| Ind-Swift Limited | 5.02 Billion INR | 64.315% |
| Innova Captab Limited | 10.81 Billion INR | 83.418% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 91.593% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 14.085% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 97.325% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 69.114% |
| Lupin Limited | 196.56 Billion INR | 99.088% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | 51.19% |
| Medico Remedies Limited | 1.44 Billion INR | -23.727% |
| Morepen Laboratories Limited | 17.01 Billion INR | 89.464% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 89.356% |
| Orchid Pharma Limited | 8.19 Billion INR | 78.117% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 84.425% |
| RPG Life Sciences Limited | 5.82 Billion INR | 69.194% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -16.152% |
| Sigachi Industries Limited | 3.98 Billion INR | 55.056% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 85.521% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 82.945% |
| Themis Medicare Limited | 3.81 Billion INR | 53.032% |
| Unichem Laboratories Limited | 16.57 Billion INR | 89.182% |
| Vaishali Pharma Limited | 862.79 Million INR | -107.82% |
| Wanbury Limited | 5.75 Billion INR | 68.852% |
| Windlas Biotech Limited | 6.3 Billion INR | 71.582% |
| ZIM Laboratories Limited | 3.67 Billion INR | 51.211% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 86.002% |
| Ipca Laboratories Limited | 77.05 Billion INR | 97.673% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.63% |
| Venus Remedies Limited | 5.91 Billion INR | 69.684% |
| Sakar Healthcare Limited | 1.54 Billion INR | -16.306% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 99.382% |
| Divi's Laboratories Limited | 78.45 Billion INR | 97.714% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 86.16% |
| Mankind Pharma Limited | 103.34 Billion INR | 98.265% |
| Sequent Scientific Limited | 13.69 Billion INR | 86.909% |
| Laurus Labs Limited | 50.01 Billion INR | 96.415% |
| Neuland Laboratories Limited | 15.58 Billion INR | 88.496% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 94.799% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 98.482% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.057% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 57.433% |
| Wockhardt Limited | 27.89 Billion INR | 93.571% |
| Bal Pharma Limited | 3.39 Billion INR | 47.142% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.358% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 76.721% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -87.48% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 89.307% |
| Shilpa Medicare Limited | 11.53 Billion INR | 84.45% |
| Valiant Laboratories Limited | 1.82 Billion INR | 1.511% |
| Ajanta Pharma Limited | 42.08 Billion INR | 95.74% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 54.677% |
| Granules India Limited | 45.06 Billion INR | 96.021% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 30.835% |
| Piramal Enterprises Limited | 60.33 Billion INR | 97.028% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 98.309% |
| NATCO Pharma Limited | 40.02 Billion INR | 95.52% |
| Suven Life Sciences Limited | 116.92 Million INR | -1433.462% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -255.615% |
| Strides Pharma Science Limited | 40.51 Billion INR | 95.574% |
| Indoco Remedies Limited | 18.17 Billion INR | 90.133% |
| Alpa Laboratories Limited | 1.08 Billion INR | -64.896% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -71.856% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -137.349% |